Microba Secures $14.5 Million to Fuel Growth, Backed by Strategic Partner Sonic Healthcare

Highlights:

• Microba Life Sciences Limited (ASX: MAP) has raised A$14.5 million through a placement and share purchase plan to support clinical adoption of its microbiome testing products.
• Strategic partner Sonic Healthcare Limited (ASX: SHL) is investing up to A$8.3 million, increasing its stake to 21.68% pending shareholder approval.
• A new UK lab agreement with The Doctors Laboratory enhances Microba’s international growth strategy while reducing operational costs.

Capital Raise to Accelerate Clinical Expansion

Microba Life Sciences Limited (ASX: MAP), a leader in microbiome health solutions, has successfully raised A$14.5 million to advance the adoption of its clinical microbiome testing products. At the time of writing, this funding round includes a two-tranche placement of A$12.5 million and a fully underwritten Share Purchase Plan (SPP) worth A$2 million. The raise attracted support from both existing and new institutional and sophisticated investors, including strategic partner Sonic Healthcare Limited (ASX: SHL), which is investing up to A$8.3 million in the initiative.

Investor Confidence Reflects Strategic Backing

Sonic Healthcare Limited remains Microba’s largest shareholder and will contribute approximately A$4.16 million in the placement, maintaining its 19.14% voting power. Subject to shareholder approval, Sonic's stake will rise to 21.68%. Microba’s Board and Management have also demonstrated their confidence by committing an additional A$290,000 to the raise. Investors will receive one unlisted option for every two shares purchased, with an exercise price of $0.14, valid for two years, subject to shareholder approval.

Capital to Support Commercial and Product Strategy

The newly raised funds will be channelled into scaling Microba’s sales, marketing, and clinical operations across Australia and the UK. The capital will also support ongoing product development, clinical validation, and strengthen working capital to underpin growth. The company has updated its FY25 revenue guidance to between A$15.4–16 million.

Partnership Strengthened with UK Agreement

In addition to the capital raise, Microba signed an exclusive commercial laboratory processing agreement with The Doctors Laboratory (TDL), a UK-based subsidiary of Sonic Healthcare. The agreement enables TDL to process Microba's tests in the UK, reducing CAPEX and accelerating international expansion.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com